Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries
- PMID: 40044295
- DOI: 10.1016/j.jacc.2024.11.048
Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries
Abstract
Background: In a context of extending transcatheter aortic valve replacement (TAVR) to patients with a longer life expectancy, it is important to better document the incidence and outcomes of reintervention.
Objectives: The authors sought to evaluate the incidence, predictive factors, and long-term outcomes of surgical (explant TAVR) or transcatheter (redo TAVR) reintervention after TAVR.
Methods: Patients who had a TAVR between 2010 and 2022 recorded in the FRANCE 2 and FRANCE TAVI registries were included in the analysis. Cumulative incidence of early (≤1 year) and late (>1 year) reintervention was assessed using the Kalbfleisch and Prentice method to account for all-cause death as a competing risk. Patients who had reintervention for infective endocarditis were excluded. Long-term mortality was evaluated using Kaplan-Meier analysis.
Results: Among 72,850 patients included, the cumulative incidence of overall reintervention at 8 years was 1.7% including 591 patients who had redo TAVR and 111 patients who required explant TAVR with a low incidence of Bentall intervention. Reintervention occurred mostly early in 62.1% of cases and was more frequent in patients who had a mean aortic gradient >20 mm Hg immediately after index TAVR. Age and mean aortic gradient before TAVR and mean aortic gradient >20 mm Hg, aortic regurgitation ≥ grade 2, and percutaneous coronary intervention after TAVR were predictive of reintervention. Six-year mortality was high but was similar in patients who had early and late reintervention (76.2% vs 64.0%; P = 0.77).
Conclusions: Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy.
Keywords: TAVR; aortic stenosis; reintervention.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Funding Support and Author Disclosures Drs Durand and Eltchaninoff have received a grant by the French Government, managed by the National Research Agency (ANR) under the program “Investissements d’avenir” with the reference ANR-16-RHUS-0003, and are supported by a grant from the GCS G4 as part of the FHU-CARNAVAL, labeled AVIESAN; and have received lecture fees from Edwards Lifesciences. Dr Tchetche has received consultancy fees from Edwards Lifesciences and Medtronic. Dr Cayla has received consultancy fees from Abbott, Edwards Lifesciences, Microport, and Shockwave; and has received grants from Amgen, AstraZeneca, Bayer Healthcare, Biotronik, Bristol Myers Squibb, Pfizer, and Sanofi. Dr Akodad has received consultancy fees from Abbott, Medtronic, and Edwards Lifesciences. Dr Dumonteil has received consultancy fees from Abbott, Ancora Heart, Boston Scientific, Edwards Lifesciences, and Medtronic. The other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical